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Vaginal melanoma is a rare disease with an overall poor prognosis.
Surgical excision is currently the modality of choice in patients with
localized disease [1]. There is a paucity of data regarding the use of
topical agents for the management of vaginal melanoma and melano-
ma in situ. However, imiquimod cream has shown to be effective in
non-gynecologic cases of lentigo melanoma with cure rates as high
as 80–100% [2]. It is infrequently used in vaginal melanoma, with
few reported cases in the literature. We report a case of recurrent
vaginal melanoma in situ successfully treated with imiquimod.
Case report
A 68-year-old woman initially presented to her primary gynecologist
in November 2009 for a routine gynecologic exam andwas noted to have
a left vaginal lesion near the hymenal ring. She underwent an excision of
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positive for melanoma in situ. Positron emission tomography (PET)
revealed diffuse FDG avid para-aortic and inguinal lymphadenopathy,
however biopsy was negative for malignancy. The lymphadenopathy
remained stable andwas thought to be reactive in nature due to previous
hip arthroplasty. There was no other evidence of metastatic disease.
The patient underwent a wide radical excision of the lesion with
lymphatic mapping and inguinal sentinel lymph node biopsy. Her
postoperative course was uncomplicated and her ﬁnal pathology rev-
ealed residual melanoma in situ without invasion (Fig. 1). The left
margin was focally positive for melanoma in situ. All lymph nodes
were negative. The patient was observed.
Four months later, the patient was noted to have multiple areas of
pigmentation on the left and right side of the vagina at the level of the
hymenal ring, as well as on the right vulva. The lesions were present
both in areas isolated from the previous surgical incisions as well as in
the area of surgical incision. The patient underwent multiple biopsies
of the lesions. Complete excision was not feasible due to the anatomic
location of the lesions. Pathology revealed melanoma in-situ with no
areas of invasion. Postoperatively, she was treated with imiquimod
5% cream. She applied the imiquimod to the affected area once week-
ly for the ﬁrst month, then twice weekly for the second month, then
three times weekly for the third and fourth months. Imiquimod was
gradually titrated to its usual dosing for vulvar dysplasia of three
times weekly in order to assess the patient's tolerance of it being ap-
plied directly in the vagina. The patient completed a total of four
months of treatment with imiquimod. She tolerated the treatment
with minimal burning or other side effects. Pelvic exam at the com-
pletion of treatment showed a complete response. PET scan showed
stable reactive lymphadenopathy with no other evidence of disease.
The patient is followed every three to four months and remains with-
out clinical evidence of recurrent melanoma in situ or invasive mela-
noma 18 months after completing therapy.Discussion
Vaginal cancer is uncommon, comprising only two to three per-
cent of all gynecologic malignancies with vaginal melanoma as the
third most common histologic type of vaginal cancer [1]. The majority
Fig. 1.Melanoma in situ: there is a diffuse proliferation of atypical epithelioidmelanocytes
along the basal layer (100×).
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limited data on the natural history of vaginal melanoma in situ. Local-
ized vaginal melanoma and melanoma in situ are typically treated
with surgical intervention. However, for patients who are not surgical
candidates or patients who have previously undergone multiple sur-
gical resections, more conservative and less radical approaches are
needed.
Tcheung et al. [3] reported 85 cases of melanoma of the female
genitalia with 15 cases of primary vaginal melanoma. The majority
of patients were treated with surgery, with a subset of patients also
receiving immunotherapy and chemotherapy. Patients who received
adjuvant therapy did not have survival differences compared to pa-
tients who were treated with surgery alone. Patients with vaginal or
cervical melanoma had poorer outcomes than those with vulvar mel-
anoma. A subsequent study by Frumovitz et al. [4] reviewed 37 cases
of stage I vaginal melanoma with similar results. The majority of pa-
tients were treated with surgery, with only 10% receiving primary ra-
diotherapy, chemotherapy or a combination of both. The median
overall survival was 19 months, however patients treated with radio-
therapy following wide local excision had reduced local recurrence
and increased overall survival.
Imiquimod was approved by the Food and Drug Administration
(FDA) for the treatment of genital warts in 1997. It has since been
shown to be extremely effective in the treatment of vulvar intra-
epithelial neoplasia (VIN). A report by van Seters et al. [5] showed
that 81% of patients with VIN treated with imiquimod had at least a
25% reduction in the size of their lesion. Furthermore, 58% of patients
cleared the HPV virus after sixteen weeks of treatment. Imiquimod
has also been used to treat many skin conditions and dermatologic
malignancies, including basal cell carcinoma and non-gynecological
melanoma [6]. Imiquimod is a topical immune-modulating agent
that stimulates synthesis and release of pro-inﬂammatory cytokines
such as interferon-alpha, interleukin-12 and tumor necrosis factor-
alpha [2]. It stimulates up regulation of antiviral and antitumor activ-
ity and thus when applied to pre-malignant or malignant lesions
leads to inﬁltration of immune cells, resulting in its antitumor effects.
In a case series of 32 patients with facial lentigo maligna treated with
daily imiquimod, 100% were found to have a complete response. One
patient recurred 30 months after completing treatment [7].There are limited data regarding the use of imiquimod for the
treatment of vulvar and vaginal melanoma in situ [8,9]. Lonsdale-
Eccles and colleagues [8] reported on a 68-year-old patient who had
experienced multiple recurrences of vulvar melanoma in situ. After nu-
merous surgeries, she elected for topical treatment with imiquimod.
She was treated for four months with a complete clinical response,
and is without evidence of disease 18 months following treatment [8].
Sadownik et al. [9] described a 72-year-old patient with recurrent mel-
anoma in situ of the vulva who was treated post operatively with
imiqiuimod. She was treated for six weeks following a wide local
excision with positive margins with complete clinical and histological
regression. She remainswithout evidence of recurrent disease 10 months
after completing treatment [9]. Similarly, Smyth et al. [10] reported on
two patients with locally recurrent vaginal mucosal melanoma treated
with imiquimod. The ﬁrst patient had a near complete resolution and
the second patient remains disease free ten years after her original
diagnosis.
In summary, we report a case of recurrent vaginal melanoma in
situ successfully treated with imiquimod. The treatment was well tol-
erated and may prove to be a useful adjunct for patients with vulvar
or vaginal melanoma in situ. Treatment with imiquimod may avoid
the disﬁgurement, pain and postoperative complications potentially
associated with repeated surgical intervention for vulvar or vaginal
melanoma in situ.
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